Healthcare provider profile · identity verified

Joyce A Vafeas, MD

Family Practice · LANCASTER, PA · NPI 1073550984

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	490	148
Lisinopril	Lisinopril	291	74
Levothyroxine Sodium	Levothyroxine Sodium	192	46
Omeprazole	Omeprazole	186	51
Amlodipine Besylate	Amlodipine Besylate	183	57
Gabapentin	Gabapentin	149	48
Metoprolol Succinate	Metoprolol Succinate	137	44
Rosuvastatin Calcium	Rosuvastatin Calcium	137	37
Alendronate Sodium	Alendronate Sodium	126	35
Hydrochlorothiazide	Hydrochlorothiazide	125	38
Metformin Hcl	Metformin Hcl	115	35
Losartan Potassium	Losartan Potassium	100	29
Metformin Hcl Er	Metformin Hcl	92	27
Pantoprazole Sodium	Pantoprazole Sodium	87	21
Furosemide	Furosemide	85	19
Trazodone Hcl	Trazodone Hcl	84	23
Sertraline Hcl	Sertraline Hcl	82	23
Montelukast Sodium	Montelukast Sodium	80	27
Simvastatin	Simvastatin	79	20
Fluticasone Propionate	Fluticasone Propionate	77	46
Tamsulosin Hcl	Tamsulosin Hcl	74	19
Metoprolol Tartrate	Metoprolol Tartrate	73	19
Bupropion Xl	Bupropion Hcl	70	20
Famotidine	Famotidine	65	18
Carvedilol	Carvedilol	63	16
Trulicity	Dulaglutide	62	13
Duloxetine Hcl	Duloxetine Hcl	59	18
Eliquis	Apixaban	54	15
Alprazolam	Alprazolam	53	17
Fluoxetine Hcl	Fluoxetine Hcl	51	11
Allopurinol	Allopurinol	50	16
Jardiance	Empagliflozin	46	15
Citalopram Hbr	Citalopram Hydrobromide	42	13
Escitalopram Oxalate	Escitalopram Oxalate	41	13
Pravastatin Sodium	Pravastatin Sodium	40	13
Atenolol	Atenolol	39	12
Clonazepam	Clonazepam	39	suppressed
Potassium Chloride	Potassium Chloride	38	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	36	suppressed
Valsartan	Valsartan	35	suppressed
Finasteride	Finasteride	34	11
Clopidogrel	Clopidogrel Bisulfate	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	11
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	29
Spironolactone	Spironolactone	31	11
Sumatriptan Succinate	Sumatriptan Succinate	31	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	29	suppressed
Oxycodone Hcl	Oxycodone Hcl	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	20
Synthroid	Levothyroxine Sodium	27	suppressed
Glipizide	Glipizide	26	suppressed
Ozempic	Semaglutide	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	15
Ibuprofen	Ibuprofen	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Diazepam	Diazepam	22	suppressed
Indapamide	Indapamide	22	suppressed
Meloxicam	Meloxicam	22	suppressed
Glipizide Er	Glipizide	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Prednisone	Prednisone	20	19
Lorazepam	Lorazepam	19	suppressed
Methimazole	Methimazole	19	suppressed
Mounjaro	Tirzepatide	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	18	16
Aripiprazole	Aripiprazole	18	suppressed
Celecoxib	Celecoxib	18	suppressed
Enalapril Maleate	Enalapril Maleate	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Levofloxacin	Levofloxacin	18	13
Alfuzosin Hcl Er	Alfuzosin Hcl	17	suppressed
Dutasteride	Dutasteride	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	17	suppressed
Risperidone	Risperidone	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	15
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Estradiol	Estradiol	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Baclofen	Baclofen	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Ibu	Ibuprofen	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Tramadol Hcl	Tramadol Hcl	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Norethindron-Ethinyl Estradiol	Norethindrone Ac/Eth Estradiol	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Victoza 3-Pak	Liraglutide	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Latuda	Lurasidone Hcl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error